Mary Varterasian - Concepedia

Author

Mary Varterasian

Also Known As

M L Varterasian, M Varterasian, M. Varterasian, M.L. Varterasian, Mary L Varterasian, Mary L. Varterasian, Mary Laura Varterasian, Mary Varterasian

157

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Wayne State University The Barbara Ann Karmanos Cancer Institute The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Mayo Clinic in Arizona

About

Mary Varterasian is an author at Wayne State University specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	542
2	Health Sciences	5	5	114
3	Blood Transplantation	3	3	62
4	Cell Biology	3	3	100
5	Natural Sciences	1	1	60

Mary Varterasian

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer John J. Rinehart, Alex A. Adjei, Patricia LoRusso, Journal of Clinical Oncology	2004	635
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú, Cancer Discovery	2017	401
Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies Patricia LoRusso, Alex A. Adjei, Mary Varterasian, Journal of Clinical Oncology	2005	397
Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses Nicholas J. Roberts, Linping Zhang, Filip Jankú, Science Translational Medicine	2014	368
Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer Oday Hamid, Mary Varterasian, Scott Wadler, Journal of Clinical Oncology	2003	144
Intratumoral Injection of <i>Clostridium novyi</i> -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors Filip Jankú, Halle Huihong Zhang, Abdulmohammad Pezeshki, Clinical Cancer Research	2020	139
Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies Jason J. Luke, Sarina A. Piha‐Paul, Theresa Medina, Clinical Cancer Research	2023	120
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Mary Varterasian, Ramzi M. Mohammad, D. Eilender, Journal of Clinical Oncology	1998	111
Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer Susana M. Campos, Oday Hamid, Michael V. Seiden, Journal of Clinical Oncology	2005	108
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Mary Varterasian, Ramzi M. Mohammad, Muhammad Shurafa, PubMed Relapsed Low-grade Non-hodgkinImmunologyPathologyPharmacotherapyImmunotherapy	2000	97

Page 1